Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: Significance of the time between initiation of adjuvant therapy and of therapy for metastatic breast cancer (multiple letters) [2]

B. Isik; K. Altundag; Carl Blomqvist

doi:10.1093/annonc/mdh023

Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: Significance of the time between initiation of adjuvant therapy and of therapy for metastatic breast cancer (multiple letters) [2]

B. Isik
, K. Altundag
, Carl Blomqvist

Hacettepe University

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	175
Number of pages	1
Journal	Annals of Oncology
Volume	15
Issue number	1
DOIs	https://doi.org/10.1093/annonc/mdh023
Publication status	Published - Jan 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/annonc/mdh023

Cite this

@article{8bfd09b55f50425585fc27b28f4c058c,

title = "Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: Significance of the time between initiation of adjuvant therapy and of therapy for metastatic breast cancer (multiple letters) [2]",

author = "B. Isik and K. Altundag and Carl Blomqvist",

year = "2004",

month = jan,

doi = "10.1093/annonc/mdh023",

language = "English",

volume = "15",

pages = "175",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "1",

}

Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: Significance of the time between initiation of adjuvant therapy and of therapy for metastatic breast cancer (multiple letters) [2]. / Isik, B.; Altundag, K.; Blomqvist, Carl.
In: Annals of Oncology, Vol. 15, No. 1, 01.2004, p. 175.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer

T2 - Significance of the time between initiation of adjuvant therapy and of therapy for metastatic breast cancer (multiple letters) [2]

AU - Isik, B.

AU - Altundag, K.

AU - Blomqvist, Carl

PY - 2004/1

Y1 - 2004/1

UR - https://www.scopus.com/pages/publications/0942298824

U2 - 10.1093/annonc/mdh023

DO - 10.1093/annonc/mdh023

M3 - Letter

C2 - 14679141

AN - SCOPUS:0942298824

SN - 0923-7534

VL - 15

SP - 175

JO - Annals of Oncology

JF - Annals of Oncology

IS - 1

ER -

Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: Significance of the time between initiation of adjuvant therapy and of therapy for metastatic breast cancer (multiple letters) [2]

UN SDGs

Access to Document

Other files and links

Cite this